Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | Director · Chairman & CEO · 10% owner | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 449,019 |
Ending reported balance
After 2026-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-05 · Exercise / conversion · Acquired 4,109 · Balance 450,294 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 2 · 2026-09-05 · Tax withholding · Disposed 2,876 · Balance 447,418 Row 3 · 2026-09-06 · Exercise / conversion · Acquired 3,455 · Balance 450,873 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 4 · 2026-09-06 · Tax withholding · Disposed 1,854 · Balance 449,019 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 17,251 |
Reported balance
After 2026-09-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-04 · Grant · Acquired 17,251 · Balance 17,251 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,330 |
Reported balance
After 2026-09-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-09-05 · Exercise / conversion · Disposed 4,109 · Balance 12,330 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,912 |
Reported balance
After 2026-09-06 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-09-06 · Exercise / conversion · Disposed 3,455 · Balance 6,912 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| Bio-Rad B Common StockSEC Table I · non-derivative | Direct | 361,466 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 361,466 |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy Spouse | 13,006 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 13,006 F2: The reporting person disclaims beneficial ownership of these shares. |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy Blue Raven Partners, L.P. | 4,060,054 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 4,060,054 F3: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy Alice N. Schwartz Revocable Trust | 1,781,356 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,781,356 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Exemption Trust | 90 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 90 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Exempt Martial Trust | 240 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 240 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Non-Exempt Martial Trust | 898,931 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 898,931 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Non-Exempt Martial Trust | 57,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 57,000 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy Charitable Remainder Unitrust | 34,311 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 34,311 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy Alice N. Schwartz Revocable Trust | 437,510 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 437,510 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: The reporting person disclaims beneficial ownership of these shares.
F3: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F6: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 35,000 | $119.80 | $4,193,000.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:50 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 12,020 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017634 · form4.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,020 Underlying: Bio-Rad A Common Stock · 12,020 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $117.50 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 20 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 39,000 shares Expires 2023-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option, representing a right to purchase a total of 39,000 shares, became exercisable in five equal annual installments beginning on September 11, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 19 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F9 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments, of which 2,600 vested on August 25, 2023. F9 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments, of which 2,600 vested on August 25, 2023. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 18 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,320 Underlying: Bio-Rad A Common Stock · 2,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments, of which 2,320 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F8 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments, of which 2,320 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,805 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 17 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,805 Underlying: Bio-Rad A Common Stock · 1,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments, of which 1,805 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments, of which 1,805 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,266 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 16 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,532 Underlying: Bio-Rad A Common Stock · 1,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments, of which 1,266 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments, of which 1,266 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,081 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 15 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,245 Underlying: Bio-Rad A Common Stock · 2,081 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments, of which 2,081 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments, of which 2,081 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 25,389 | $381.78 | $9,693,012.42 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 12 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,300 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 39,000 | $117.50 | $4,582,500.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 11 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,290 | $381.78 | $492,496.20 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 10 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,920 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 9 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,151 | $381.78 | $439,428.78 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,610 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 895 | $381.78 | $341,693.10 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,441 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 628 | $381.78 | $239,757.84 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,531 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,032 | $381.78 | $393,996.96 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,893 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| November 07, 2022 Filed Dec 1, 2022 21:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023089 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,900 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| November 07, 2022 Filed Dec 1, 2022 21:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023089 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,689 Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · derivative · entry 15 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 5, 2017, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On September 5, 2017, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,575 | $478.32 | $753,354.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,844 Read SEC document |
| September 05, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · derivative · entry 14 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Bio-Rad A Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,575 | $478.32 | $753,354.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,819 Read SEC document |
| September 04, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,319 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · derivative · entry 13 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,640 Underlying: Bio-Rad A Common Stock · 2,319 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,405 | $478.32 | $672,039.60 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,794 Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,805 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · derivative · entry 12 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,610 Underlying: Bio-Rad A Common Stock · 1,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,094 | $478.32 | $523,282.08 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,880 Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 18:24 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019290 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,266 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019202 · form4.xml · derivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,798 Underlying: Bio-Rad A Common Stock · 1,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 8,326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019202 · form4.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,326 Underlying: Bio-Rad A Common Stock · 8,326 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 767 | $486.25 | $372,953.75 |
DisclosureSEC source: 0001062993-22-019202 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,169 Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 18:10 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-019202 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 23:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 39,250 | $0.00 Strike: $107.32 | $0.00 |
DisclosureSEC source: 0001062993-22-018842 · form4.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 39,250 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 39,250 shares, became exercisable in five equal annual installments beginning on September 12, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 23:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 23,749 | $495.28 | $11,762,404.72 |
DisclosureSEC source: 0001062993-22-018842 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,647 Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 23:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 39,250 | $107.32 | $4,212,310.00 |
DisclosureSEC source: 0001062993-22-018842 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:30 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011448 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,858 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| November 09, 2021 Filed Nov 23, 2021 19:30 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 20 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011448 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,146 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $100.06 | $0.00 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · derivative · entry 9 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 37,000 shares Expires 2021-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 37,000 shares, became exercisable in five equal annual installments beginning on November 4, 2012, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · derivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class B common stock. F5 · derivative.exercise_date: On September 7, 2016, the reporting person was granted 15,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 7, 2016, the reporting person was granted 15,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 20,660 | $806.32 | $16,658,571.20 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,126 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 37,000 | $100.06 | $3,702,220.00 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 1,488 | $806.32 | $1,199,804.16 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,786 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 13:39 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008418 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class B common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2021 Filed Sep 8, 2021 16:09 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-008356 · form4.xml · derivative · entry 12 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Bio-Rad A Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 5, 2017, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 5, 2017, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.